P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial — Myeloma Research News

P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from the first three patients enrolled in a Phase 1 trial show. The three patients received the lowest dose of P-BCMA-101. Based on the findings, the company is now recruiting additional myeloma patients to receive the next dose in the…

via P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial — Myeloma Research News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.